Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Alprostadil Liposome in Healthy Volunteers
NCT03669562Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2018
- Primary completion
- Oct 2018
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised trial of Alprostadil Liposomes for Injection in lower extremity arterial occlusive disease (LEAOD) (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 8 days. Status: unknown.
02
Drugs
Alprostadil Liposomes for Injection
03
Conditions
lower extremity arterial occlusive disease (LEAOD)
Beyond the preview
Go deeper on NCT03669562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03669562.